Seed round · open

$5M.
SEIS / EIS eligible.

Raising to build the native AI stack, scale the live products globally, and convert the shipped demos into commercial products. SEIS/EIS-eligible for UK-taxpaying investors via Advanced Subscription. International investors via SAFE on the same terms.

Round size
$5M
Seed · SEIS / EIS eligible
Products shipped
4
Two live · two in public demo · MHRA Class I
Combined TAM 2028
$290B+
Across twelve verified market segments
Countries in use
7
Three continents · zero marketing spend
Why now

The next 18 months decide the winner.

01 · foundation open

Open-weight models caught up to proprietary.

The defensible IP is now the corpus and the training — not the base model. The window to compile a proprietary medical reasoning layer is open.

02 · regulation ready

Most products are Non-Device CDS in the US.

MHRA Class I in hand. FDA January 2026 guidance enables the bulk of the roadmap without submission. EU MDR, FDA De Novo and APAC pathways sequenced for the one true device.

03 · clinician demand

Seven countries · zero marketing.

Physicians actively pulling the product. PLG traction exists. The next 18 months decide which ecosystem becomes the default.

Investment highlights

Why GacruxAI is differentiated.

Deployed, not pitched

  • ClinixSummary live with paying clinicians across seven countries and three continents
  • ClinixQM live with a sovereign-deployment story
  • MHRA Class I · ISO 13485-aligned · SEIS/EIS Advance Assurance granted
  • Two preprints on Research Square (Springer Nature) with registered DOIs, plus two pre-registered validation studies — published research
  • Proven shipping cadence — no decks-only risk

Compounding moat

  • One backbone · fifteen interconnected products · same reasoning
  • Trained weights plus the proprietary corpus — 3–5 year reproduction lead
  • Marginal cost of the next product approaches zero
  • Single-product copying doesn't replicate the ecosystem

Stacked revenue model

  • Clinicians, enterprise health systems, medical schools, pharma R&D
  • Same accounts, multiple complementary revenue lines
  • A single pharma engagement matches thousands of clinician subscriptions
  • Non-device CDS pathway opens the US from Y1H2

Founder-market fit

  • Practising physician built the live product end-to-end
  • Technical leadership in healthcare data infra and AI integration
  • Commercial leadership with prior startup growth and pharma BD relationships
  • Clinical Safety Officer in seat from day one
Data room available on request

Talk to the founder.

Full financial model, TAM-bottom-up, use of funds, architecture detail, competitive teardown and customer references — all in the data room. Access on request to verified investors.

Request data room access Schedule a call